

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attn: Mr. Winston M. Alvarado
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On May 22, 2007

TOWNSEND and TOWNSEND and CREW LLP

By: Corinna Joss
Corinna Joss

PATENT
Attorney Docket No.: 015280-478100US
Customer No.: 45115

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LEPPLA *et al.*

Application No.: 10/554,076

Filed: October 21, 2005

For: ACTIVATION OF
RECOMBINANT DIPHTHERIA TOXIN
FUSION PROTEINS BY SPECIFIC
PROTEASES HIGHLY EXPRESSED
ON THE SURFACE OF TUMOR CELLS

Confirmation No. 4475

Examiner: Not yet assigned

Art Unit: Not yet assigned

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Attn: Mr. Winston M. Alvarado
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) mailed January 22, 2007, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification as follows.

Amendments to the Specification begin on page 3 of this paper.

Appl. No. 10/554,076

Amdt. dated May 22, 2007

Reply to Notification of Missing Requirements of January 22, 2007

PATENT

Amendments to the Claims are reflected in the listing of claims which begins on page 4 of this paper.

Remarks begin on page 10 of this paper.